£235.00
50 in stock
For research use only — Not for human or animal use
Retatrutide 60mg Pen is a triple receptor agonist developed by Eli Lilly and studied for its effects on metabolism, appetite signalling, and body weight regulation. Unlike earlier compounds that focus on a single pathway, Retatrutide targets GLP-1, GIP, and glucagon receptors together.
This multi-pathway approach has made it one of the most discussed compounds in current metabolic research, particularly in studies linked to weight management and blood glucose regulation. Researchers are especially interested in how these hormone pathways may work together to influence appetite, energy expenditure, and long-term metabolic response.
Retatrutide is designed to activate three separate hormone receptors involved in metabolism and appetite control:
By combining these pathways into one receptor agonist, researchers are exploring whether Retatrutide may produce broader metabolic effects compared to single-pathway compounds. This has led to comparisons with other similar weight loss injections, including Wegovy and Mounjaro.
Interest in Retatrutide increased significantly following early clinical trial data exploring its effects on body weight and metabolic signalling.
Researchers are particularly interested in how weekly dosing schedules and gradually increased exposure may influence appetite regulation, blood sugar response, and long-term metabolic adaptation.
Studies have also explored how activating receptors GLP-1, GIP, and glucagon together may affect:
Ongoing clinical trials continue evaluating long-term outcomes, maintenance dose response, and how Retatrutide compares to earlier receptor agonist compounds. As with similar compounds, side effects are still being studied. Reported observations in clinical trials have included mild to moderate gastrointestinal effects in some participants.
| Compound | Primary Targets | Research Focus |
|---|---|---|
| Semaglutide | GLP-1 | Appetite regulation and blood sugar control |
| Tirzepatide | GLP-1 + GIP | Metabolism, appetite signalling, and weight management |
| Retatrutide | GLP-1 + GIP + Glucagon | Combined metabolic signalling, energy expenditure, and body weight regulation |
Because Retatrutide includes glucagon receptor activity in addition to GLP-1 and GIP pathways, researchers are studying whether this added mechanism may influence energy balance differently compared to earlier compounds.
The Retatrutide 60mg Pen should be stored under refrigerated conditions and protected from excessive heat or direct light exposure.
Standard handling practices include:
Responses can vary depending on observation period, weekly dosing structure, and maintenance dose approach used during studies.
Disclaimer: This product is sold strictly for research purposes only. Not for human consumption.
